Transgene Biotek Limited Reports Q3 FY26 Net Loss of ₹37.38 Lakhs
Transgene Biotek Limited reported a net loss of ₹37.38 lakhs for Q3 FY26 ended December 31, 2025, significantly higher than the ₹8.90 lakhs loss in Q3 FY25. Revenue from operations declined 28.76% to ₹5.45 lakhs, while total expenses more than doubled to ₹42.82 lakhs, primarily due to finance costs surging to ₹27.35 lakhs. For the nine-month period, the company posted a loss of ₹119.59 lakhs against a profit of ₹3.70 lakhs in the previous year.
*this image is generated using AI for illustrative purposes only.
Transgene Biotek Limited has announced its unaudited standalone and consolidated financial results for the quarter ended December 31, 2025, revealing significant operational challenges with widening losses and declining revenue performance.
Financial Performance Overview
The company reported a substantial increase in net losses for the third quarter of FY26, with both standalone and consolidated results showing identical figures due to minimal subsidiary operations.
| Metric | Q3 FY26 | Q3 FY25 | Change |
|---|---|---|---|
| Revenue from Operations | ₹5.45 lakhs | ₹7.65 lakhs | -28.76% |
| Total Income | ₹5.45 lakhs | ₹12.03 lakhs | -54.69% |
| Total Expenses | ₹42.82 lakhs | ₹20.93 lakhs | +104.59% |
| Net Loss | ₹37.38 lakhs | ₹8.90 lakhs | +319.89% |
Revenue and Income Analysis
The company's revenue from operations declined to ₹5.45 lakhs in Q3 FY26 from ₹7.65 lakhs in Q3 FY25, representing a decrease of 28.76%. The decline was more pronounced in total income, which fell from ₹12.03 lakhs to ₹5.45 lakhs, primarily due to the absence of other income that contributed ₹4.38 lakhs in the previous year quarter.
Expense Structure and Cost Pressures
Total expenses more than doubled to ₹42.82 lakhs in Q3 FY26 from ₹20.93 lakhs in Q3 FY25. The most significant contributor to this increase was finance costs, which surged to ₹27.35 lakhs from ₹1.73 lakhs in the corresponding quarter of the previous year.
| Expense Category | Q3 FY26 | Q3 FY25 | Change |
|---|---|---|---|
| Employee Benefits | ₹3.31 lakhs | ₹8.15 lakhs | -59.39% |
| Finance Costs | ₹27.35 lakhs | ₹1.73 lakhs | +1,481.50% |
| Depreciation | ₹4.98 lakhs | ₹2.32 lakhs | +114.66% |
| Other Expenses | ₹7.18 lakhs | ₹8.73 lakhs | -17.76% |
Nine-Month Performance
For the nine-month period ended December 31, 2025, the company's performance deteriorated significantly. Revenue from operations declined to ₹15.68 lakhs from ₹18.42 lakhs in the corresponding period of the previous year. The company reported a net loss of ₹119.59 lakhs for the nine-month period compared to a profit of ₹3.70 lakhs in the previous year.
Other Expenses Breakdown
The detailed breakdown of other expenses for Q3 FY26 shows legal and professional charges as the largest component at ₹3.24 lakhs, followed by PCB renewal costs of ₹2.87 lakhs. Other significant expenses included contractual expenses of ₹0.27 lakhs and advertisement costs of ₹0.22 lakhs.
Corporate Governance and Legal Matters
The company continues to deal with several ongoing legal proceedings. The matter in SAT has a hearing scheduled for February 24, 2026, while the hearing at the Appellate Tribunal, New Delhi is set for April 14, 2026. Additionally, the appeal at NCLT Hyderabad bench is scheduled for March 3, 2026. The company reported no complaints pending or received during the quarter.
Board Approval and Audit
The financial results were approved by the Board of Directors at a meeting held on February 13, 2026, which commenced at 11:00 a.m. and concluded at 11:45 a.m. The results underwent limited review by M/s Vasavi & Co, Chartered Accountants, who provided unqualified review reports for both standalone and consolidated financial statements.
Historical Stock Returns for Transgene Biotek
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +6.43% | +28.02% | -4.68% | -44.68% | -40.18% | -32.05% |
17
